Sanofi pays milestone to Rib-X
Rib-X’s RX-04 program employs a proprietary approach for rational drug design resulting in entirely novel classes of compounds. Recently presented data confirmed the new compounds directly impact ribosome
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.